Opinion|Videos|November 18, 2026

PIRA in MS: Recognizing Progression Independent of Relapse Activity

Progression independent of relapse activity persists even on highly effective therapy. It is a clinical phenomenon, and the patient's own account is often the earliest and most reliable signal.

"PIRA in MS: Recognizing Progression Independent of Relapse Activity" asks how clinicians should recognize worsening that occurs without a relapse.

Dr. Greenberg observes that trials once centered on relapses now focus on confirmed disability progression, and he asks Dr. Singer about progression independent of relapse activity, or PIRA. Dr. Singer contrasts it with relapse-associated worsening, in which disability accrues over the month or two after a relapse. PIRA describes patients who worsen without relapses, and a percentage still do so on highly effective therapy, including B-cell depletion.

Dr. Singer stresses that PIRA is a clinical phenomenon measured by disability change, not a pathophysiology. Some of it may reflect delayed effects of acute injury, such as retinal nerve fiber layer thinning on OCT months after optic neuritis, or spinal cord volume loss after transverse myelitis. Yet he believes PIRA speaks mainly to compartmentalized inflammation that current treatments do not address. Monoclonal antibodies are too large to enter the central nervous system, and brain-penetrant oral agents have not yet tackled these mechanisms. He hopes BTK inhibition will help and urges careful monitoring in clinic.

Dr. Greenberg describes three camps of monitoring: anatomic imaging such as OCT and MRI, biologic markers, and clinical assessment. He notes the literature anchors PIRA to the EDSS and asks whether it exists beyond that scale. Dr. Singer answers yes and says clinicians should first listen to the patient. Patients report that walking has become harder, balance is worse, cognition is impaired, or work is a struggle.

Dr. Singer adds that listening is essential because clinicians will miss progression otherwise. He has used an iPad-based processing speed test since 2019, which gives him raw scores and z-scores over time compared with people without MS. He asks how else clinicians will objectively monitor walking and cognition to know when progression is happening.

The next episode in this series, "Beyond Relapses and MRI: Practical Ways to Monitor MS Control," features Dr. Krieger on practical assessment strategies for busy clinics.


Related to this article